Superior and specific antitumor responses exhibited by SmarT cells.

Slides:



Advertisements
Similar presentations
AF647-RIS is internalized by TAMs in vivo.
Advertisements

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.
Volume 22, Issue 3, Pages (March 2014)
Volume 25, Issue 3, Pages (March 2017)
The STM1787 promoter in Salmonella is rapidly activated in vivo by the tumor microenvironment. The STM1787 promoter in Salmonella is rapidly activated.
Validation of St6GalNAc2 as a metastasis suppressor gene.
DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.
Fig. 4. Antitumor efficacy of ERY974 against various cancer types.
Estrogen drives accumulation of myelomonocytic (M-MDSC) and granulocytic (G-MDSC) MDSCs and increases the immunosuppressive potential of G-MDSCs. Estrogen.
Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.
Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.
Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor
Bioluminescence imaging facilitates detection of tumor growth and metastasis in mouse orthotopic xenograft model. Bioluminescence imaging facilitates detection.
Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. (A)
Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.
IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells. IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells.
Vaccine MN confer protective innate and adaptive immunity.
CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.
Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.
Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.
The contributions of anti-Ad antibody and T-cell responses to viral clearance in tumor and antitumor efficacy of Ad5 therapy. The contributions of anti-Ad.
Antitumor immunity caused by DS-8201a.
In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s
E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective breast tumors. E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective.
Socially isolated SV40 Tag mice develop significantly larger mammary gland tumors. Socially isolated SV40 Tag mice develop significantly larger mammary.
coTCRcys-transduced T cells control tumor growth in vivo.
Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.
EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,
Accelerated metastasis spread in tumor-bearing mice treated with paclitaxel and anakinra. Accelerated metastasis spread in tumor-bearing mice treated with.
Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c
Antitumor activity of MLN8237 against TNBC patient-derived tumor xenografts (PDTX) in vivo. Antitumor activity of MLN8237 against TNBC patient-derived.
Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.
The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.
In vivo efficacy of targeted EDVTM in an orthotopic neuroblastoma mouse model with high EGFR protein levels. In vivo efficacy of targeted EDVTM in an orthotopic.
ESKM is superior to ESK1 in vivo, and is effective against multiple tumor models. ESKM is superior to ESK1 in vivo, and is effective against multiple tumor.
Micro-PET/CT images of 64Cu-Sar-chTNT-3 in MAD109-bearing BALB/c mice following VP-16 pretreatment. Micro-PET/CT images of 64Cu-Sar-chTNT-3 in MAD109-bearing.
GM-CSF is required for CA-MSC–induced tumor metastasis.
Effect of the crystal form and solid dispersion preparations of KRN633 on the growth of human tumor xenografts in mice. Effect of the crystal form and.
SY-1425 induces maturation in RARA-high AML
Tumor cell clusters with increased tumorigenesis, metastasis, and CD44 expression. Tumor cell clusters with increased tumorigenesis, metastasis, and CD44.
Determination of MTD for romidepsin and pralatrexate and associated antitumor activity. Determination of MTD for romidepsin and pralatrexate and associated.
HMQ1611 inhibited breast tumor growth in mice.
The CD8+ cytotoxic T-cell response in Ron TK−/− hosts in response to tumors is necessary and sufficient to block metastasis. The CD8+ cytotoxic T-cell.
Loss of HDAC3 inhibits CREBBP-mutant lymphoma growth in vitro and in vivo. Loss of HDAC3 inhibits CREBBP-mutant lymphoma growth in vitro and in vivo. A,
In vivo bioluminescence imaging of primary tumors and tumor metastasis
A and B, intratumoral DC-AdCCL21 leads to reduction in growth rates of bilateral tumors. A and B, intratumoral DC-AdCCL21 leads to reduction in growth.
A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.
C7R enhances adoptive T-cell immunotherapy against metastatic and intracranial malignancies.A and B, 1 × 106 CHLA-255 FFluc cells were injected i.v. into.
Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.
Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.
CDV potentiates the antitumor effect of ionizing radiation in mice intracerebrally implanted with human glioblastoma cells. CDV potentiates the antitumor.
Mean body weights (grams) of athymic female mice implanted with MDA-MB-231 breast carcinoma xenografts. Mean body weights (grams) of athymic female mice.
MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.
Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.
Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.
T cells with a ROR1-specific CAR eliminate tumor cells in vivo only with a modified long spacer. T cells with a ROR1-specific CAR eliminate tumor cells.
PDL192 and inhibit the growth of xenograft tumors.
A, antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against “sensitive” Ewing.
BCMab1 confers Fc-FcγR–dependent antitumor activity through both macrophages and NK cells. BCMab1 confers Fc-FcγR–dependent antitumor activity through.
Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.
Effects of ZOL treatment on pulmonary metastases.
Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor cells after weekly CAR+ T-cell treatment for 4 wks. Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor.
IL35 regulation of tumor growth is accompanied by suppression of CD4+ effector T-cell activity and expansion of Tregs. IL35 regulation of tumor growth.
BV6 increases bone metastasis.
Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.
Ex vivo profiling of PD-1 blockade using MDOTS
AMG 176 exhibits robust single-agent activity in vivo.
Dose-dependent effect of IP6 feeding on angiogenesis in prostate of TRAMP mice. Dose-dependent effect of IP6 feeding on angiogenesis in prostate of TRAMP.
T cells expressing a KIR-CAR/Dap12 show potent in vivo antitumor activity that is resistant to the tumor-induced T-cell hypofunction observed with CD3ζ-based.
AXL knockout does not prevent dormancy.
Presentation transcript:

Superior and specific antitumor responses exhibited by SmarT cells. Superior and specific antitumor responses exhibited by SmarT cells. A, Schematic of animal model where NSG mice were engrafted with dual tumors—CAPAN-1 PSCA only (left flank) and CAPAN-1 PSCA + TGFβ + IL4 + (right flank)—and treated with SmarT cells labeled with firefly luciferase (FFluc+). B, Representative mice images and (C, D) quantification of SmarT-cell signal detected by bioluminescence imaging (n = 5–6 replicates per experiment with a maximum SEM of 0.01E+09 and 0.4E+09 photons/sec in the PSCA and PSCA + IL4 + TGFβ groups on day 18, respectively. However, the error bars are too small to be appreciated in C. E and F, Antitumor responses determined by calipers to assess tumor volume. (Although the maximum error bars for the PSCA and PSCA + IL4 + TGFβ groups are 96 and 29 mm3 on days 47 and 12, respectively, they are too small to be appreciated in E and F.) G and H, Superimposition of SmarT-cell signal against tumor volume. Data represent mean ± SEM (n = 5–6 mice per group). Sujita Sukumaran et al. Cancer Discov 2018;8:972-987 ©2018 by American Association for Cancer Research